Pharma News

FDA Issues Complete Response Letter to Supernus for SPN-830, a Potential Treatment for Motor Fluctuations in Parkinson Disease

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

Source link
#FDA #Issues #Complete #Response #Letter #Supernus #SPN830 #Potential #Treatment #Motor #Fluctuations #Parkinson #Disease

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *